Concert Pharmaceuticals Inc (CNCE) Quote

Sun Pharma Completes Acquisition of Concert Pharmaceuticals (3/06/23)

- Acquisition Adds Deuruxolitinib, a Potential Best-in-Class Oral JAK Inhibitor for the Treatment of Alopecia Areata, to Sun Pharma's Global Dermatology Portfolio

MUMBAI, India and PRINCETON, N.J., March 6, 2023 /PRNewswire/ -- Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715 (together with its subsidiaries and/or associated companies, "Sun Pharma")) today announced the successful completion of its acquisition of Concert Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company that is developing deuruxolitinib, a novel, deuterated, oral JAK1/2 inhibitor, for the potential treatment of adult patients with moderate to severe alopecia areata.

"We are excited to add deuruxolitinib, a late-stage, potential best-in-class treatment for alopecia areata, to our growing global dermatology portfolio and expand our presence in the Boston biotech hub," said Abhay Gandhi, CEO North America, Sun Pharma. "By bringing together Concert's talented team with Sun Pharma's global reach and commercial capabilities, this acquisition is an opportunity to bring deuruxolitinib to market globally and make a meaningful difference to alopecia areata patients around the world."

Sun Pharma's tender offer to acquire all outstanding shares of Concert's common stock for (i) $8.00 per share in cash, subject to any applicable withholding of taxes and without interest (the "Common Cash Amount"), plus (ii) one non-transferable contingent value right (each, a "CVR") per share (the "Common CVR Amount" and together with the Common Cash Amount, the "Offer Price"), subject to any applicable withholding of taxes and without interest, which represents the contractual right to receive contingent payments of up to $3.50 per share, in cash, in the aggregate, subject to any applicable withholding of taxes and without interest, upon the achievement of certain milestones described below prior to December 31, 2029, expired one minute after 11:59 p.m. New York City time on Friday, March 3, 2023. The depositary for the tender offer has advised that, as of the expiration of the tender offer, a total of 48,220,511 shares of Concert's common stock were validly tendered and not withdrawn in the tender offer, which represent approximately 75.2% of the total number of shares of Concert's outstanding common stock.

Following the acceptance of the tendered shares, Sun Pharma completed the acquisition of Concert through the merger of a wholly owned subsidiary of Sun Pharma with and into Concert in which (i) each share of Concert's common stock not tendered into the offer (other than shares (a) held in Concert's treasury, (b) owned by Sun Pharma, any subsidiary of Sun Pharma or any subsidiary of Concert or (c) shares held by Concert stockholders who properly demanded appraisal for their shares under Delaware law) was converted into the right to receive the Offer Price and (ii) each share of Concert's Series X1 Preferred Stock (other than shares (a) held in Concert's treasury or (b) shares held by Concert stockholders who properly demanded appraisal for their shares under Delaware law) was converted into the right to receive (1) the Common Cash Amount multiplied by 1,000, in cash, subject to any applicable withholding of taxes and without interest, plus (2) the Common CVR Amount multiplied by 1,000, subject to any applicable withholding of taxes and without interest, which represents the right to receive contingent payments of up to $3.50 per CVR, in cash, in the aggregate, subject to any applicable withholding of taxes and without interest, upon the achievement of certain milestones prior to December 31, 2029. As a result of the merger, Concert became a wholly owned subsidiary of Sun Pharma. The common stock of Concert will no longer be listed for trading on the Nasdaq Global Market.

For additional background on the acquisition, please read the announcement press release here.

About Deuruxolitinib and Alopecia Areata

Deuruxolitinib is an investigational oral selective inhibitor of Janus kinases JAK1 and JAK2. The U.S. Food and Drug Administration recently maintained Breakthrough Therapy designation for deuruxolitinib for the treatment of adult patients with moderate to severe alopecia areata and previously granted Fast Track designation for deuruxolitinib for the treatment of alopecia areata.

Alopecia areata is an autoimmune disease in which the immune system attacks hair follicles, resulting in partial or complete loss of hair on the scalp and body. Alopecia areata may affect up to 2.5% of the United States and global population during their lifetime.1,2,3 The scalp is the most commonly affected area, but any hair-bearing site can be affected alone or together with the scalp. Onset of the disease can occur throughout life and affects both women and men. Alopecia areata can be associated with serious psychological consequences, including anxiety and depression. There are currently limited treatment options available for alopecia areata.

Disclaimer:

Statements in this "Document" describing the Company's objectives, projections, estimates, expectations, plans or predictions or industry conditions or events may be "forward looking statements" within the meaning of applicable securities laws and regulations. Actual results, performance or achievements could differ materially from those expressed or implied. The Company undertakes no obligation to update or revise forward looking statements to reflect developments or circumstances that arise or to reflect the occurrence of unanticipated developments/circumstances after the date hereof.

References:

Benigno M. A Large Cross-Sectional Survey Study of the Prevalence of Alopecia Areata in the United States, Clinical, Cosmetic and Investigational Dermatology 2020.
Lee HH et al. Epidemiology of alopecia areata, ophiasis, totalis, and universalis: A systematic review and meta-analysis, J Am Acad Dermatol. 2020 Mar; 82(3):675-682.
Fricke et al. Epidemiology and burden of alopecia areata: a systematic review, Clin Cosmet Investig Dermatol. 2015 Jul 24;8:397-403.)
About Sun Pharmaceutical Industries Limited (CIN - L24230GJ1993PLC019050)

Sun Pharma is the world's fourth largest specialty generic pharmaceutical company and India's top pharmaceutical company. A vertically integrated business and a skilled team enables it to deliver high-quality products, trusted by customers and patients in over 100 countries across the world, at affordable prices. Its global presence is supported by manufacturing facilities spread across six continents and approved by multiple regulatory agencies, coupled with a multi-cultural workforce comprising over 50 nationalities. Sun Pharma fosters excellence through innovation supported by strong R&D capabilities across multiple R&D centers, with investments of approximately 6% of annual revenues in R&D. For further information, please visit www.sunpharma.com and follow us on Twitter @SunPharma_Live.

https://www.prnewswire.com/news-releases/sun-pharma-completes-acquisition-of-concert-pharmaceuticals-301763327.html

Wish it would get back to 28

Took a year to get back to today price range a break of this range
Will take us to double digits
Price targets.

It’s like clockwork
Always on time!!!

Looks like we won our patent case! Now we just need pos p3 data and were off!

There has to be some reason why they are paying more than market price for offering. I believe this will go up from here. It bottomed out. There will be follow-up news once offering is closed. Also, they is no risk of dilution until end of 2022 since they will have enough money to conduct trial.

Hello $CNCE
I like what I see here
Looks like we ready!!!!
Grateful for the opportunity !!!!
Let’s go $CNCE—————>

Now to 30's

Headed to 20's now

Let's hold the line at 17

Headed to 18 boys and girls

CNCE coming back to $14

$CNCE recent news/filings

bullish

## source: finance.yahoo.com

Wed, 27 May 2015 11:29:06 GMT ~ Concert Pharmaceuticals to Present at Two Upcoming Investor Conferences

[at noodls] - LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the following upcoming investor conferences: The Jefferies ...

read full: http://www.noodls.com/view/D231E016A766700686ED07DBBBF100FBE0715CFA
*********************************************************

Wed, 27 May 2015 11:00:00 GMT ~ Concert Pharmaceuticals to Present at Two Upcoming Investor Conferences

[Business Wire] - Concert Pharmaceuticals, Inc. today announced that it will present a corporate overview at the following upcoming investor conferences:

read full: http://finance.yahoo.com/news/concert-pharmaceuticals-present-two-upcoming-110000567.html
*********************************************************

Tue, 19 May 2015 17:04:19 GMT ~ CONCERT PHARMACEUTICALS, INC. Financials


read full: http://finance.yahoo.com/q/is?s=cnce
*********************************************************

Tue, 12 May 2015 11:12:17 GMT ~ Concert Pharmaceuticals to Present at the UBS Global Healthcare Conference

[at noodls] - LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the UBS Global Healthcare Conference onTuesday, May 19, 2015 ...

read full: http://www.noodls.com/view/30C3FCF74EC30E6DF22D872C636C50B9F2C672D3
*********************************************************

Tue, 12 May 2015 11:00:00 GMT ~ Concert Pharmaceuticals to Present at the UBS Global Healthcare Conference

[Business Wire] - Concert Pharmaceuticals, Inc. today announced that it will present a corporate overview at the UBS Global Healthcare Conference on Tuesday, May 19, 2015 at 11:30 a.m.

read full: http://finance.yahoo.com/news/concert-pharmaceuticals-present-ubs-global-110000268.html
*********************************************************

$CNCE charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com



$CNCE company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CNCE/company-info
Ticker: $CNCE
OTC Market Place: Not Available
CIK code: not found
Company name: Concert Pharmaceuticals, Inc.
Incorporated In:



$CNCE share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

$CNCE extra dd links

Company name: Concert Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CNCE+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CNCE+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CNCE+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/news - http://finance.yahoo.com/q/h?s=CNCE+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CNCE/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CNCE+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CNCE
DTCC (dtcc.com): http://search2.dtcc.com/?q=Concert+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Concert+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Concert+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CNCE
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CNCE&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CNCE
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CNCE+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CNCE+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CNCE
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CNCE
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CNCE+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CNCE/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CNCE+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CNCE.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CNCE
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CNCE
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CNCE
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CNCE:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CNCE
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CNCE



$CNCE DD Notes ~ http://www.ddnotesmaker.com/CNCE

Sounds cool. I just loaded last week. You are not playing CLDN?

Only stock I am buying right now. Time will make this one huge and only thing holding it back is fear of conception. It has been proved and needs a good article or news to make it really really BIG.
Mean time, I am hoping for a failure on the JAZZ trial. That would drive it down a few bucks and allow much more loading...

Double in 4 weeks?

CNCE buy at 15s? Could it double in the next two months? Thanks

Finally breaking out...

$CNCE NEWS: Jazz Pharmaceuticals and Concert Pharmaceuticals Provide JZP-386 Program Update

Last update: 09/12/2014 8:30:00 am

DUBLIN & LEXINGTON, Mass.--(BUSINESS WIRE)--December 09, 2014--

Jazz Pharmaceuticals plc (NASDAQ:JAZZ) and Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that Phase 1 clinical data generated to date supports completing the Phase 1 evaluation of JZP-386 at the originally planned highest dose, which was not administered in the first Phase 1 trial due to a technical dosing issue. The existing Phase 1 clinical data was generated in a first-in-human trial evaluating the safety, pharmacokinetics, and pharmacodynamics of JZP-386; enrollment was completed in the third quarter. A second Phase 1 trial evaluating JZP-386 at the originally planned highest dose is expected to be initiated in the first quarter of 2015, with data expected in the second quarter of 2015.

JZP-386 is a deuterium-containing analog of sodium oxybate. The Phase 1 program is comparing JZP-386 to sodium oxybate versus placebo in healthy volunteers. The companies expect that the results from the upcoming Phase 1 trial will inform the next steps in the development program for JZP-386.

Sodium oxybate is the active ingredient in Xyrem(R), a prescription medicine marketed in the United States by Jazz Pharmaceuticals to treat cataplexy and excessive daytime sleepiness in patients with narcolepsy, a serious neurological disorder that affects approximately 1 in 2000 people in the United States.

About Jazz Pharmaceuticals plc

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing and commercializing differentiated products that address unmet medical needs. The company has a diverse portfolio of products and/or product candidates in the areas of sleep, hematology/oncology, pain and psychiatry. The company's U.S. marketed products in these areas include: Xyrem(R) (sodium oxybate) oral solution, Erwinaze(R) (asparaginase Erwinia chrysanthemi), Prialt(R) (ziconotide) intrathecal infusion, Versacloz(R) (clozapine) oral suspension, FazaClo(R) (clozapine, USP) HD and FazaClo LD. Jazz Pharmaceuticals also has a number of products marketed outside the United States, including Erwinase(R) and Defitelio(R) (defibrotide). For more information, please visit www.jazzpharmaceuticals.com.

About Concert Pharmaceuticals

Concert Pharmaceuticals is a clinical stage biopharmaceutical company focused on applying its DCE Platform(R) (deuterated chemical entity platform) to create novel small molecule drugs. This approach starts with approved drugs, advanced clinical candidates or previously studied compounds that have the potential to be improved with deuterium substitution to enhance clinical safety, tolerability and efficacy. The Company is developing a broad pipeline targeting CNS disorders, renal disease, inflammation and cancer. For more information, please visit www.concertpharma.com.

About Xyrem

Xyrem(R) (sodium oxybate) oral solution, CIII, is indicated for the treatment of cataplexy in narcolepsy and for the treatment of EDS in narcolepsy. Xyrem may only be dispensed to patients enrolled in the Xyrem Success Program(R). Xyrem was first approved in the United States in 2002. Safety and effectiveness in pediatric patients have not been established.


IMPORTANT SAFETY INFORMATION
------------------------------------------------------------------------------
XYREM is a Central Nervous System (CNS) depressant. In clinical trials at
recommended doses, obtundation and clinically significant respiratory
depression occurred in XYREM-treated patients. Almost all of the patients who
received XYREM during clinical trials in narcolepsy were receiving CNS
stimulants. XYREM is the sodium salt of gamma hydroxybutyrate (GHB). Abuse of
GHB, either alone or in combination with other CNS depressants, is associated
with CNS adverse reactions, including seizure, respiratory depression,
decreases in the level of consciousness, coma, and death. Because of the risks
of CNS depression, abuse, and misuse, XYREM is available only through a
restricted distribution program called the XYREM Success Program(R), using a
centralized pharmacy. Prescribers and patients must enroll in the program. For
further information go to www.XYREM.com or call 1-866-XYREM88(R)
(1-866-997-3688).



Xyrem is contraindicated in combination with sedative hypnotics or alcohol and in patients with succinic semialdehyde dehydrogenase deficiency. Use caution when considering the concurrent use of Xyrem with other CNS depressants. Healthcare providers should caution patients against hazardous activities requiring complete mental alertness or motor coordination within the first 6 hours of dosing or after first initiating treatment until certain that Xyrem does not affect them adversely. Xyrem is a Schedule III controlled substance. The rapid onset of sedation, coupled with the amnestic features of Xyrem, particularly when combined with alcohol, has proven to be dangerous for the voluntary and involuntary user (e.g. assault victim). Monitor patients for emergent or increased depression and suicidality and for impaired motor/cognitive function. Episodes of sleepwalking should be fully evaluated and appropriate interventions considered. Consider the amount of daily sodium intake in each dose of Xyrem in patients sensitive to salt intake.

Jazz Pharmaceuticals plc "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995

This press release contains forward-looking statements, including, but not limited to, statements related to future events in the Phase 1 clinical program for JZP-386, the timing of the second Phase 1 clinical trial, the therapeutic potential of JZP-386 and other statements that are not historical facts. These forward-looking statements are based on Jazz Pharmaceuticals' current expectations and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, risks and uncertainties associated with the timing and conduct of clinical trials and the therapeutic value of JZP-386; the uncertainty of regulatory approval; and those risks with respect to research and development and clinical trials detailed from time-to-time under the caption "Risk Factors" and elsewhere in Jazz Pharmaceuticals plc's Securities and Exchange Commission filings and reports (Commission File No. 001-33500), including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2014, and future filings and reports by Jazz Pharmaceuticals. Jazz Pharmaceuticals undertakes no duty or obligation to update any forward-looking statements contained in this press release as a result of new information, future events or changes in its expectations.

Concert Pharmaceuticals Cautionary Note on Forward Looking Statements

Any statements in this press release about our future expectations, plans and prospects, including statements about the future clinical development of JZP-386, the potential effectiveness of JZP-386, our plans and timelines for the clinical development of JZP-386 and other statements containing the words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "should," "target," "would," and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation of future clinical trials, availability and timing of data from ongoing and future clinical trials and the results of such trials, whether preliminary results from a clinical trial will be predictive of the final results of that trial or whether results of early clinical trials will be indicative of the results of later clinical trials, expectations for regulatory approvals and other factors discussed in the " Risk Factors" section of our most recent Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission and in other filings that we make with the Securities and Exchange Commission. In addition, any forward-looking statements included in this press release represent our views only as of the date of this release and should not be relied upon as representing our views as of any subsequent date. We specifically disclaim any obligation to update any forward-looking statements included in this press release.

Concert Pharmaceuticals Inc., the CoNCERT Pharmaceuticals Inc. logo and DCE Platform are registered trademarks of Concert Pharmaceuticals, Inc.

Jazz Pharmaceuticals and the Jazz Pharmaceuticals logo are registered trademarks of Jazz Pharmaceuticals plc or its subsidiaries.

Photos/Multimedia Gallery Available: www.businesswire.com/multimedia/home/20141209005304/en/

CONTACT: Jazz Pharmaceuticals plc

(investors)

Katherine Littrell, PhD, RN, U.S. + 650-496-2717

Ireland + 353 1 634 7887

investorinfo@jazzpharma.com

or

(media)

Laurie Hurley, U.S. + 1-650-496-2796

Ireland + 353 1 634 7894

or

Concert Pharmaceuticals

(investors)

Justine Koenigsberg, U.S. + 781-674-5284

ir@concertpharma.com

or

(media)

The Yates Network

Kathryn Morris, U.S. + 845-635-9828

SOURCE: Jazz Pharmaceuticals plc and Concert Pharmaceuticals, Inc.
Copyright Business Wire 2014


(END) Dow Jones Newswires

December 09, 2014 08:30 ET (13:30 GMT)

No reason for drop BUY !

A patent issued... Still holding out hopes that AVNR does not sell out.

bing... Nice empty board... Stay away !!!!!!!

$CNCE DD Notes ~ http://www.ddnotesmaker.com/CNCE

bullish
double bottom W pattern

$CNCE recent news/filings

## source: finance.yahoo.com

Wed, 15 Oct 2014 21:04:59 GMT ~ Concert Pharmaceuticals Announces Positive CTP-354 Data


read full: http://finance.yahoo.com/news/concert-pharmaceuticals-announces-positive-ctp-210459839.html
*********************************************************

Mon, 13 Oct 2014 11:00:00 GMT ~ Concert Pharmaceuticals Presents Positive Data from Multiple Dose Phase 1 Clinical Trial of CTP-354, Lead Candidate for the Treatment of Spasticity

[Business Wire] - Concert Pharmaceuticals, Inc. announced today Phase 1 data of CTP-354, a novel, potentially first-in-class, non-sedating, once-daily oral treatment for spasticity. In this multiple ascending dose trial, no sedation or ataxia was observed with CTP-354 and the drug was generally well tolerated across all dose cohorts.

read full: http://finance.yahoo.com/news/concert-pharmaceuticals-presents-positive-data-110000779.html
*********************************************************

Mon, 29 Sep 2014 16:07:00 GMT ~ Five Reasons Celgene Could Gain 20%


read full: http://blogs.barrons.com/stockstowatchtoday/2014/09/29/five-reasons-celgene-could-gain-20/?mod=yahoobarrons&ru=yahoo
*********************************************************

Wed, 17 Sep 2014 11:00:00 GMT ~ Concert Pharmaceuticals Announces Initiation of CTP-730 Phase 1 Clinical Trial Under Celgene Collaboration

[Business Wire] - Concert Pharmaceuticals, Inc. today announced that it has initiated a Phase 1 clinical trial of CTP-730, a novel product candidate that is being developed under its strategic collaboration with Celgene Corporation.

read full: http://finance.yahoo.com/news/concert-pharmaceuticals-announces-initiation-ctp-110000464.html
*********************************************************

Tue, 16 Sep 2014 11:02:52 GMT ~ Concert Pharmaceuticals (CNCE) Soars: Stock Rises 25.8%


read full: http://finance.yahoo.com/news/concert-pharmaceuticals-cnce-soars-stock-110252735.html
*********************************************************


$CNCE charts

basic chart ## source: stockcharts.com



basic chart ## source: stockscores.com



big daily chart ## source: stockcharts.com



big weekly chart ## source: stockcharts.com


$CNCE company information

## source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CNCE/company-info
Ticker: $CNCE
OTC Market Place: Not Available
CIK code: not found
Company name: Concert Pharmaceuticals, Inc.
Incorporated In:


$CNCE share structure

## source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available
$CNCE extra dd links

Company name: Concert Pharmaceuticals, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=CNCE+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=CNCE+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=CNCE+Industry

## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/news - http://finance.yahoo.com/q/h?s=CNCE+Headlines

## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/CNCE/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=CNCE+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/CNCE
DTCC (dtcc.com): http://search2.dtcc.com/?q=Concert+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Concert+Pharmaceuticals%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Concert+Pharmaceuticals%2C+Inc.&x=0&y=0

## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/CNCE
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/sec-filings
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=CNCE&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=CNCE
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=CNCE+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=CNCE+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=CNCE
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=CNCE
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=CNCE+Cash+Flow&annual

## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/CNCE/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=CNCE+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/CNCE.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=CNCE
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/CNCE/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/CNCE/insider-transactions

## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/CNCE
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/CNCE
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/CNCE:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=CNCE
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CNCE



$CNCE DD Notes ~ http://www.ddnotesmaker.com/CNCE

No one even knows about the 923 data on value to Concert. They have big value coming in already on what avinir is selling now AVP -786. The other will be an ADD ON.

That is a PR that is yet to be determined. Not sure as to what the royalities are, I have read that it covers their burn rate at the very least.

If JAZZ uses it, sky is the limit.

It is time to sit on the sidelines and just hold for a while. No volome what so ever and the reason,..... no one will sell...

I am impressed this has held up.

I think it is 4, just submit they will let you know if something is missing.

Or is it 3 posts.

Think you need 2 posts within 24 hours to become a MOD.

I am going to rework this page so everyone understands what the DCE platform is and how it works. It is making Avinir a name in meds, going to help JAA and Celegene too.

More... More again... Me... and Me too...

Suprised...

Get it cheaper, just wait a week or 2.. Nothing happening between then and now.

$CNCE $CELG Roth Capital Reiterates Buy On Concert Following Initiation Of Phase I Study http://www.smarteranalyst.com/2014/09/18/roth-capital-reiterates-buy-concert-following-initiation-phase-study/

I am loading up for a lifetime on the next BIG pullback. If fact, wish they had some type of failure. Their founder is brilliant and brought what he knew with him. Their compound are the wave of future medicine.. I hope...

So many medicines fail on poor metabolic stability resulting in failed phase trial testing. Would bet that is why AVINIR was able to bring forth something no one ever thought of...

This leaves Concert in the drivers seat for so so many things. Baker Bros knew to buy them early and you can bet the will go in and get a huge offering at some point...

They are making money, although not enough... The AVP-786 is only the begining for these guys...

I was scepticle until this last trial by AVNR... Now we know... Imagine making a pain reliever that last 3 times longer... What is that worth...OMG !

Everybody was late off of the news... Considering what they do they are a great play, at this price I wouldn't touch it. THey have a way's to go to make any money. As they grow, they can increase their value and stance...

Yup...

What is the symbol CNCE

Beast tomorrow?!?!

Concert Pharmaceuticals, Inc. [$CNCE] due diligence

bullish
$CNCE

DD Notes ~ http://www.ddnotesmaker.com/CNCE

##### recent news/filings ~ source: finance.yahoo.com

Thu, 26 Jun 2014 18:06:38 GMT ~ BUZZ-U.S. Stocks on the Move-Royale Energy, Methode, Concert Pharma
read full: http://uk.finance.yahoo.com/news/buzz-u-stocks-move-royale-180638948.html
*********************************************************

Mon, 16 Jun 2014 20:37:12 GMT ~ CONCERT PHARMACEUTICALS, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and
read full: http://biz.yahoo.com/e/140616/cnce8-k.html
*********************************************************

Tue, 27 May 2014 11:00:00 GMT ~ Concert Pharmaceuticals to Present at Upcoming Investor Conferences
[Business Wire] - Concert Pharmaceuticals, Inc. today announced that it will present at the following upcoming conferences:
read full: http://finance.yahoo.com/news/concert-pharmaceuticals-present-upcoming-investor-110000248.html
*********************************************************

Tue, 20 May 2014 17:04:25 GMT ~ CONCERT PHARMACEUTICALS, INC. Financials
read full: http://finance.yahoo.com/q/is?s=cnce
*********************************************************

Wed, 14 May 2014 11:16:56 GMT ~ CONCERT PHARMACEUTICALS, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements
read full: http://biz.yahoo.com/e/140514/cnce8-k.html
*********************************************************

##### chart ~ source: stockcharts.com



##### chart ~ source: eoddata.com



##### company info ~ source: otcmarkets.com

Link: http://www.otcmarkets.com/stock/CNCE/company-info
Ticker: $CNCE
OTC Market Place: Not Available
CIK code: not found
Company name: Concert Pharmaceuticals, Inc.
Incorporated In:

##### extra dd links

Latest filings: http://www.otcmarkets.com/stock/CNCE/filings
Latest financials: http://www.otcmarkets.com/stock/CNCE/financials
Latest news: http://www.otcmarkets.com/stock/CNCE/news - http://finance.yahoo.com/q/h?s=CNCE+Headlines

Major holdings: http://data.cnbc.com/quotes/CNCE/tab/8.1
Insider transactions (1): http://finance.yahoo.com/q/it?s=CNCE+Insider+Transactions
Insider transactions (2): http://www.secform4.com/insider-trading/CNCE.htm
Insider transactions (3): http://www.insidercow.com/history/company.jsp?company=CNCE

RegSho: http://www.regsho.com/tools/symbol_stats.php?sym=CNCE&search=search

DTCC: http://search2.dtcc.com/?q=Concert+Pharmaceuticals%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information: http://www.spoke.com/search?utf8=%E2%9C%93&q=Concert+Pharmaceuticals%2C+Inc.
Corporation WIKI: http://www.corporationwiki.com/search/results?term=Concert+Pharmaceuticals%2C+Inc.&x=0&y=0

Short Sales: http://www.otcmarkets.com/stock/CNCE/short-sales
Insider Disclosure: http://www.otcmarkets.com/stock/CNCE/insider-transactions
Research Reports: http://www.otcmarkets.com/stock/CNCE/research
Historical Prices: http://finance.yahoo.com/q/hp?s=CNCE+Historical+Prices
Basic Tech. Analysis: http://finance.yahoo.com/q/ta?s=CNCE+Basic+Tech.+Analysis
Company Profile: http://finance.yahoo.com/q/pr?s=CNCE+Profile
Key Statistics: http://finance.yahoo.com/q/ks?s=CNCE+Key+Statistics
Industry: http://finance.yahoo.com/q/in?s=CNCE+Industry
Insider Roster: http://finance.yahoo.com/q/ir?s=CNCE+Insider+Roster
Income Statement: http://finance.yahoo.com/q/is?s=CNCE
Balance Sheet: http://finance.yahoo.com/q/bs?s=CNCE
Cash Flow: http://finance.yahoo.com/q/cf?s=CNCE+Cash+Flow&annual
Market Watch: http://www.marketwatch.com/investing/stock/CNCE
Bloomberg: http://www.bloomberg.com/quote/CNCE:US
Morningstar: http://quotes.morningstar.com/stock/s?t=CNCE
Bussinessweek: http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=CNCE
Barchart: http://www.barchart.com/quotes/stocks/CNCE
OTC Short Report: http://otcshortreport.com/index.php?index=CNCE
Investopedia: http://www.investopedia.com/markets/stocks/CNCE/?wa=0

http://www.pennystocktweets.com/stocks/profile/CNCE

##### last known share structure ~ source: otcmarkets.com

Market Value: Not Available
Shares Outstanding: Not Available
Float: Not Available
Authorized Shares: Not Available
Par Value: Not Available

##### business description ~ source: otcmarkets.com



DD Notes ~ http://www.ddnotesmaker.com/CNCE
cube1